Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-05-04, Stock:NVS, The news for the past five days is as follows:
2018-04-27: NEWS1: Biotech Stocks Facing FDA Decision In May.NEWS2: Biotech Stocks Facing FDA Decision In May.NEWS3: How Vertex Pharmaceuticals’ Drugs Performed in 1Q18.NEWS4: GlaxoSmithKline’s 1Q18 Earnings: Revenue Trend.NEWS5: How Did BioMarin Pharmaceutical Perform in 1Q18?.NEWS6: Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat.NEWS7: Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat.NEWS8: What's in the Cards for Conatus (CNAT) This Earnings Season?.NEWS9: What's in the Cards for Conatus (CNAT) This Earnings Season?.NEWS10: Greek parliament cannot investigate Novartis case, committee says.NEWS11: Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1?.NEWS12: Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1?.NEWS13: The Swiss Stock Market Finished Little Changed In Choppy Trade.NEWS14: The Swiss Stock Market Finished Little Changed In Choppy Trade.
2018-04-30: NEWS1: FDA Oks Tafinlar + Mekinist For Adjuvant Treatment Of BRAF V600-mutant Melanoma.NEWS2: FDA Oks Tafinlar + Mekinist For Adjuvant Treatment Of BRAF V600-mutant Melanoma.NEWS3: Teva: ‘Hold’ Ratings from 55% of Analysts before 1Q18 Results.NEWS4: Analysts Raise Teva’s Earnings Estimates before Its 1Q18 Results.NEWS5: Could Teva Exceed Analysts’ Sales Estimates for 1Q18?.NEWS6: GlaxoSmithKline’s 1Q18 Earnings: Consumer Healthcare Business.NEWS7: The Swiss Stock Market Climbed On Roche Strength.NEWS8: The Swiss Stock Market Climbed On Roche Strength.
2018-05-01: NEWS1: U.S. approves Novartis cell therapy for lymphoma.NEWS2: Novartis says Kymriah receives second U.S. FDA approval.NEWS3: Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates.NEWS4: Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates.NEWS5: Breakthrough cancer therapy developed at Penn receives 2nd FDA approval.NEWS6: Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings.NEWS7: GlaxoSmithKline’s Valuation after 1Q18 Earnings.NEWS8: Pfizer tops earnings estimates, driven by sales of pneumonia vaccine Prevnar.NEWS9: Novartis provides update on proposed acquisition of AveXis.NEWS10: Novartis-AveXis Deal Receives U.S. Regulatory Approval.NEWS11: Novartis-AveXis Deal Receives U.S. Regulatory Approval.
2018-05-02: NEWS1: MorphoSys Posts Wider Loss In Q1; Confirms 2018 Financial Guidance - Quick Facts.NEWS2: MorphoSys Posts Wider Loss In Q1; Confirms 2018 Financial Guidance - Quick Facts.NEWS3: Sandoz Gets Complete Response Letter From FDA For Proposed Biosimilar Rituximab.NEWS4: Sandoz Gets Complete Response Letter From FDA For Proposed Biosimilar Rituximab.NEWS5: What Lies Ahead for Ligand (LGND) This Earnings Season?.NEWS6: What Lies Ahead for Ligand (LGND) This Earnings Season?.NEWS7: VXUS, NSRGY, TSM, NVS: Large Inflows Detected at ETF.NEWS8: VXUS, NSRGY, TSM, NVS: Large Inflows Detected at ETF.NEWS9: NVS and NVO: Which Has Higher Upside Potential?.NEWS10: These Pharma Stocks Offer the Most Upside Potential.NEWS11: The Swiss Stock Market Inched Higher Ahead Of Fed Announcement.NEWS12: The Swiss Stock Market Inched Higher Ahead Of Fed Announcement.NEWS13: Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings.NEWS14: For Expensive New Drugs, Biopharma Should Make Money-Back Guarantees Mandatory.NEWS15: Here’s What’s Moving SIGA and Novartis.
2018-05-03: NEWS1: Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates.NEWS2: Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates.NEWS3: [$$] We Were Winning the War Against Malaria.NEWS4: Conatus&apos; (CNAT) Q1 Loss In Line, Revenues Beat Estimates.NEWS5: The Swiss Stock Market Pulled Back On Broad Weakness.NEWS6: The Swiss Stock Market Pulled Back On Broad Weakness.NEWS7: Free Research Report as Novartis’ Sales Jumped 10% and Core EPS Advanced 13%.NEWS8: What Lies Ahead for Ligand (LGND) This Earnings Season? (Revised).NEWS9: What Lies Ahead for Ligand (LGND) This Earnings Season? (Revised).NEWS10: Roche wins reprieve as Novartis biosimilar delayed in U.S..NEWS11: Novartis biosimilar cancer drug hits U.S. regulatory bump.

Answer: Rise